Literature DB >> 31908596

Androgen receptor splice variant 7 (AR-V7) and AR full-length (AR-FL) as predictive biomarkers of therapeutic resistance: partners in crime?

Roberto H Barbier1, Cindy H Chau1, William D Figg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31908596      PMCID： PMC6943979          DOI： 10.1111/bju.14869

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  6 in total

1.  Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer.

Authors:  Howard I Scher; Ryon P Graf; Nicole A Schreiber; Anuradha Jayaram; Eric Winquist; Brigit McLaughlin; David Lu; Martin Fleisher; Sarah Orr; Lori Lowes; Amanda Anderson; Yipeng Wang; Ryan Dittamore; Alison L Allan; Gerhardt Attard; Glenn Heller
Journal:  JAMA Oncol       Date:  2018-09-01       Impact factor: 31.777

2.  Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer.

Authors:  Yezi Zhu; Adam Sharp; Courtney M Anderson; John L Silberstein; Maritza Taylor; Changxue Lu; Pei Zhao; Angelo M De Marzo; Emmanuel S Antonarakis; Mindy Wang; Xingyong Wu; Yuling Luo; Nan Su; Daniel Nava Rodrigues; Ines Figueiredo; Jonathan Welti; Emily Park; Xiao-Jun Ma; Ilsa Coleman; Colm Morrissey; Stephen R Plymate; Peter S Nelson; Johann S de Bono; Jun Luo
Journal:  Eur Urol       Date:  2017-09-01       Impact factor: 20.096

3.  AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer.

Authors:  Marzia Del Re; Stefania Crucitta; Andrea Sbrana; Eleonora Rofi; Federico Paolieri; Giulia Gianfilippo; Luca Galli; Alfredo Falcone; Riccardo Morganti; Camillo Porta; Eleni Efstathiou; Ron van Schaik; Guido Jenster; Romano Danesi
Journal:  BJU Int       Date:  2019-05-04       Impact factor: 5.588

4.  Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY.

Authors:  Scott T Tagawa; Emmanuel S Antonarakis; Ada Gjyrezi; Giuseppe Galletti; Seaho Kim; Daniel Worroll; John Stewart; Atef Zaher; Ted P Szatrowski; Karla V Ballman; Katsuhiro Kita; Shinsuke Tasaki; Yang Bai; Luigi Portella; Brian J Kirby; Fred Saad; Mario A Eisenberger; David M Nanus; Paraskevi Giannakakou
Journal:  Clin Cancer Res       Date:  2018-10-09       Impact factor: 12.531

5.  Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.

Authors:  Andrew J Armstrong; Susan Halabi; Jun Luo; David M Nanus; Paraskevi Giannakakou; Russell Z Szmulewitz; Daniel C Danila; Patrick Healy; Monika Anand; Colin J Rothwell; Julia Rasmussen; Blair Thornburg; William R Berry; Rhonda S Wilder; Changxue Lu; Yan Chen; John L Silberstein; Gabor Kemeny; Giuseppe Galletti; Jason A Somarelli; Santosh Gupta; Simon G Gregory; Howard I Scher; Ryan Dittamore; Scott T Tagawa; Emmanuel S Antonarakis; Daniel J George
Journal:  J Clin Oncol       Date:  2019-03-13       Impact factor: 44.544

6.  Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.

Authors:  Adam Sharp; Ilsa Coleman; Wei Yuan; Cynthia Sprenger; David Dolling; Daniel Nava Rodrigues; Joshua W Russo; Ines Figueiredo; Claudia Bertan; George Seed; Ruth Riisnaes; Takuma Uo; Antje Neeb; Jonathan Welti; Colm Morrissey; Suzanne Carreira; Jun Luo; Peter S Nelson; Steven P Balk; Lawrence D True; Johann S de Bono; Stephen R Plymate
Journal:  J Clin Invest       Date:  2018-11-26       Impact factor: 14.808
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.